- Home
- CPRX vs DYN Comparison
CPRX vs DYN Comparison
Compare CPRX & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRX | DYN |
|---|---|---|
| Founded | 2002 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CPRX | DYN |
|---|---|---|
| Price | $31.28 | $16.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $35.00 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.3M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.24 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $119,072,803.00 | N/A |
| Revenue This Year | $9.20 | N/A |
| Revenue Next Year | $10.51 | N/A |
| P/E Ratio | $62.54 | ★ N/A |
| Revenue Growth | ★ 16.39 | N/A |
| 52 Week Low | $19.05 | $8.25 |
| 52 Week High | $32.56 | $25.00 |
Technical Indicators
Market Signals| Indicator | CPRX | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 72.04 | 42.44 |
| Support Level | $31.00 | $16.46 |
| Resistance Level | $31.33 | $19.54 |
| Average True Range (ATR) | 0.07 | 1.03 |
| MACD | -0.20 | -0.08 |
| Stochastic Oscillator | 77.78 | 20.59 |
Price Performance
Historical ComparisonAbout CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.